Claims for Patent: 7,998,506

Summary for Patent: 7,998,506

Title:	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
Abstract:	An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day "nocturnally," that is in the evening or at night.
Inventor(s):	Bova; David J (Boca Raton, FL)
Assignee:	KOS Life Sciences, Inc. (Weston, FL)
Application Number:	10/444,145
Patent Claims:	1. A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of: dosing the hyperlipidemic once a day, in the evening or at night, with at least one sustained release solid oral dosage form comprising (i) about 375 mg of nicotinic acid; (ii) about 5% to about 50% by weight of hydroxypropyl methylcellulose; (iii) about 1% to about 5% by weight of povidone; and (iv) about 0.5% to about 2.0% by weight of stearic acid, wherein the hyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the hyperlipidemic's HDL cholesterol is increased, wherein the total amount of nicotinic acid dosed to a hyperlipidemic in a day is between about 1000 to about 3000 mgs. 2. A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of: dosing the hyperlipidemic once a day, in the evening or at night, with at least one sustained release solid oral dosage form comprising (i) about 500 mg of nicotinic acid; (ii) about 5% to about 50% by weight of hydroxypropyl methylcellulose; (iii) about 1% to about 5% by weight of povidone; and (iv) about 0.5% to about 2.0% by weight of stearic acid, wherein the hyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the hyperlipidemic's HDL cholesterol is increased, wherein the total amount of nicotinic acid dosed to a hyperlipidemic in a day is between about 1000 to about 3000 mgs. 3. A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of: dosing the hyperlipidemic once a day, in the evening or at night, with at least one sustained release solid oral dosage form comprising (i) about 750 mg of nicotinic acid; (ii) about 5% to about 50% by weight of hydroxypropyl methylcellulose; (iii) about 1% to about 5% by weight of povidone; and (iv) about 0.5% to about 2.0% by weight of stearic acid, wherein the hyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the hyperlipidemic's HDL cholesterol is increased, wherein the total amount of nicotinic acid dosed to a hyperlipidemic in a day is between about 1000 to about 3000 mgs. 4. A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of: dosing the hyperlipidemic once a day, in the evening or at night, with at least one sustained release solid oral dosage form comprising (i) about 1000 mg of nicotinic acid; (ii) about 5% to about 50% by weight of hydroxypropyl methylcellulose; (iii) about 1% to about 5% by weight of povidone; and (iv) about 0.5% to about 2.0% by weight of stearic acid, wherein the hyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the hyperlipidemic's HDL cholesterol is increased, wherein the total amount of nicotinic acid dosed to a hyperlipidemic in a day is between about 1000 to about 3000 mgs.